587 related articles for article (PubMed ID: 9531570)
21. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
[TBL] [Abstract][Full Text] [Related]
22. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
[TBL] [Abstract][Full Text] [Related]
23. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
[TBL] [Abstract][Full Text] [Related]
24. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.
Wong CW; Privalsky ML
J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306
[TBL] [Abstract][Full Text] [Related]
25. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.
Khan MM; Nomura T; Kim H; Kaul SC; Wadhwa R; Shinagawa T; Ichikawa-Iwata E; Zhong S; Pandolfi PP; Ishii S
Mol Cell; 2001 Jun; 7(6):1233-43. PubMed ID: 11430826
[TBL] [Abstract][Full Text] [Related]
26. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
[TBL] [Abstract][Full Text] [Related]
27. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
28. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
29. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
30. The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain.
Sitterlin D; Tiollais P; Transy C
Oncogene; 1997 Mar; 14(9):1067-74. PubMed ID: 9070655
[TBL] [Abstract][Full Text] [Related]
31. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
[TBL] [Abstract][Full Text] [Related]
32. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
33. Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level.
Qiu J; Huang Y; Chen G; Chen Z; Tweardy DJ; Dong S
Mol Biol Cell; 2007 Oct; 18(10):3941-51. PubMed ID: 17671166
[TBL] [Abstract][Full Text] [Related]
34. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
35. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells.
Benedetti L; Levin AA; Scicchitano BM; Grignani F; Allenby G; Diverio D; Lo Coco F; Avvisati G; Ruthardt M; Adamo S; Pelicci PG; Nervi C
Blood; 1997 Aug; 90(3):1175-85. PubMed ID: 9242550
[TBL] [Abstract][Full Text] [Related]
37. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
38. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
Beez S; Demmer P; Puccetti E
PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
[TBL] [Abstract][Full Text] [Related]
39. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers.
Lin RJ; Evans RM
Mol Cell; 2000 May; 5(5):821-30. PubMed ID: 10882118
[TBL] [Abstract][Full Text] [Related]
40. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]